Who are Autologous Engineered Skin Substitute's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Platelet Rich Plasma (PRP), Leukocyte rich platelet rich plasma, AMNIOGEN, PRF is added in the test group., Autologous platelets rich plasma, prolotherapy solution of 20% dextrose.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/autologous-engineered-skin-substitute.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Autologous Engineered Skin Substitute — Competitive Intelligence Brief

Autologous Engineered Skin Substitute (Autologous Engineered Skin Substitute) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Regenerative medicine. Area: Dermatology.

phase 2 Regenerative medicine Dermatology Small molecule Live · refreshed every 30 min

Target snapshot

Autologous Engineered Skin Substitute (Autologous Engineered Skin Substitute) — Amarantus BioScience Holdings, Inc.. Autologous Engineered Skin Substitute is a regenerative medicine that uses a patient's own cells to promote skin healing.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class
Autologous Engineered Skin Substitute TARGET	Autologous Engineered Skin Substitute	Amarantus BioScience Holdings, Inc.	phase 2	Regenerative medicine
Platelet Rich Plasma (PRP)	Platelet Rich Plasma (PRP)	Aspetar	marketed	Autologous cell therapy / Regenerative medicine
Leukocyte rich platelet rich plasma	Leukocyte rich platelet rich plasma	University Hospitals Cleveland Medical Center	marketed	Autologous cell therapy / Regenerative medicine product
AMNIOGEN	AMNIOGEN	Kaohsiung Veterans General Hospital.	marketed	Biological tissue product / Regenerative medicine
PRF is added in the test group.	PRF is added in the test group.	University of Aarhus	marketed	Regenerative medicine / Biomaterial
Autologous platelets rich plasma	Autologous platelets rich plasma	Mostafa Hassanein, Msc	marketed	Autologous cell therapy / Regenerative medicine product
prolotherapy solution of 20% dextrose	prolotherapy solution of 20% dextrose	Hadassah Medical Organization	marketed	Regenerative medicine agent

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Regenerative medicine class)

Amarantus BioScience Holdings, Inc. · 1 drug in this class
CUTISS AG · 1 drug in this class
Massachusetts General Hospital · 1 drug in this class
zhang li · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Autologous Engineered Skin Substitute — Competitive Intelligence Brief. https://druglandscape.com/ci/autologous-engineered-skin-substitute. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab